Beà Sílvia, Amador Virginia
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBER de Cáncer, C/Rosselló 149-153, 08036, Barcelona, Spain.
Curr Oncol Rep. 2017 Jun;19(6):43. doi: 10.1007/s11912-017-0598-1.
Mantle cell lymphoma (MCL) is an aggressive lymphoid neoplasm, incurable with current therapies. The t(11;14)(q13;q32) involving cyclin D1 is considered the first oncogenic hit found in virtually all MCLs. However, additional secondary genomic alterations are essential for complete transformation. MCLs are genetically very unstable with several genetic alterations associated with its high proliferative behavior involving several oncogenic pathways. Furthermore, SOX11 is overexpressed in the majority of conventional MCLs (cMCL), including cyclin D1-negative cases, but absent in non-nodal leukemic MCL with indolent clinical behavior (nnMCL). Recent data have revealed the potential oncogenic role of SOX11 in MCL biology, highlighting its implication in tumor aggressiveness and progression. This review addresses the implication of SOX11 overexpression and frequent genetic lesions, cooperating with cyclin D1 underlying the pathogenesis of this aggressive disease.
套细胞淋巴瘤(MCL)是一种侵袭性淋巴瘤,目前的治疗方法无法治愈。涉及细胞周期蛋白D1的t(11;14)(q13;q32)被认为是几乎所有MCL中发现的首个致癌性突变。然而,额外的继发性基因组改变对于完全转化至关重要。MCL在基因上非常不稳定,有几种与高增殖行为相关的基因改变,涉及多个致癌途径。此外,SOX11在大多数传统MCL(cMCL)中过度表达,包括细胞周期蛋白D1阴性病例,但在具有惰性临床行为的非结内白血病性MCL(nnMCL)中不存在。最近的数据揭示了SOX11在MCL生物学中的潜在致癌作用,突出了其在肿瘤侵袭性和进展中的作用。本综述探讨了SOX11过表达和常见基因损伤的影响,以及它们与细胞周期蛋白D1协同作用在这种侵袭性疾病发病机制中的作用。